(MENAFN- PR Newswire)
DUBLIN, June 23, 2022 /PRNewswire/ -- The 'Mass Spectrometry Market - Forecasts from 2022 to 2027' report has been added to ResearchAndMarkets.com's offering.
Mass spectrometry is a process carried out to find the mass to charge (m/z) ratio of molecules present in a sample to be tested. The mass to charge ratio helps find useful information like the exact molecular weight of a molecule present, which can lead to identifying an unknown compound.
Mass spectrometry also helps understand different chemical properties and structural orientations of the molecules present in the testing sample. It adopts the ionization of the molecules by an ionization source, followed by acceleration so that the ions have equal kinetic energy.
Under the influence of both electric and magnetic fields, the ions deflect in accordance with the charge present on them, and finally, they are detected electrically via a detector present at the end of the spectrometric system. The real-life applications of the mass spectrometry market are vast in pharmaceutical, drug, biotechnology, and other similar sectors. With high R&D investments and developments in the pharmaceutical as well as the biotechnology industry, the growth in the mass spectrometry market is anticipated to increase substantially during the forecast period.
However, the advanced technological setup needed for successful mass spectroscopy research comes at expensive pricing. It may take significantly longer periods to develop, which is quite a challenge to overcome by this industry, hence negatively impacting the market share. Also, the lack of skill and technical knowledge needed to carry out precise and accurate mass spectrometry will be a preliminary factor restraining the mass spectrometry market size globally during the forecast period and beyond.
COVID-19 Impact on the Mass Spectrometry Market
The recent coronavirus pandemic has affected significant industries across the whole planet in a negative manner. However, exceptions exist, such as the mass spectrometry market. The birth of the pandemic has raised concerns for the safety of the population against similar ailments in the future and hence led to high research and development initiatives along with major investments in the pharma and biotech industry. As the pharma industry, along with biotech, gets ready for future advancements, the market for mass spectroscopy is highly anticipated to rise during the forecasted period and beyond as well.
High R&D initiatives in the pharmaceutical and biotech segment
The pharmaceutical and biotech industry have witnessed significant funding and R&D investment and are anticipated to add to the numbers in both dimensions. As per the Biotechnology Innovation Report (BIO) 2020, the number of patents granted in the US in the biotechnology field rose about 17% from 2016 to 2019. Also, the same report (BIO) stated that the venture capital investments from the years 2016 to 2019 totalled to exceed USD 102 billion, with 2018 and 2019 crossing the USD 30 billion mark.
Additionally, as per the United States Congressional Budget Office report released in April 2021, the US biopharmaceutical industry invested USD 83 billion on R&D in the year 2019, which is nearly ten times the amount spent in the 1980s every year. In a 2020 data report published by the European Federation of Pharmaceutical Industries and Associations (EFPIA), the EU-28 pharmaceutical industry invested EUR 37.5 billion in R&D.
The same report stated an investment of about EUR 14 billion in pharmaceutical R&D by Japan. With high R&D investments and capital funding, the pharma and biotech industry is in for rapid future growth; thus, their rise is anticipated to propel the market size of mass spectrometry in the forecast period. Lack of talent, Expensive pricing, and long periods to develop
The manufacturing of mass spectrometers and related devices can be too complex in design, and they come at high prices to the end consumer, such as pharma and biotech companies. In a journal published in October 2019 by Wiley Analytical Science, a spectrometer required for space applications can take up to a decade to manufacture and even cost a couple of million dollars.
Such expensive pricing and complex design can seem unfeasible for several potential user companies of the mass spectrometry market to adopt on a high scale level. According to the 2021 Technology and Innovation Report of the United Nations Conference on Trade and Development (UNCTAD), in the highly technical field of gene- editing, there lies a shortage of scientific personnel with relevant experience globally, with a higher shortage in developing countries. Such factors are expected to restrain the mass spectrometry market globally during the forecast period.
US to see significant growth in the Mass Spectrometry Market
The United States of America is projected to grow substantially in the global mass spectrometry market share. As per the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) 2021 Facts and Figures Report, the spending on the pharma industry by the US will increase from USD 485 billion in 2018 to approximately USD 650 billion in 2023 at a CAGR of 4-7% which is higher than the projected global increase. With high R&D investments and government-aided funding, the mass spectrometry market share worldwide is projected to rise for the US in the forecast period.
Key Topics Covered: 1. Introduction 2. Research Methodology 3. Executive Summary 4. Market Dynamics 4.1. Market Drivers4.2. Market Restraints4.3. Porter's Five Forces Analysis4.3.1. Bargaining Power of End-Users4.3.2. Bargaining Power of Buyers4.3.3. Threat of New Entrants4.3.4. Threat of Substitutes4.3.5. Competitive Rivalry in the Industry4.4. Industry Value Chain Analysis 5. Global Mass Spectrometry Analysis, By Mass Analyzer/Ion Separation 5.1. Introduction5.2. Quadrupole Mass Analyzer5.3. Time of flight Mass Analyzer5.4. Magnetic Sector Mass Analyzer5.5. Electrostatic Mass Analyzer5.6. Quadrupole Ion Trap Mass Analyzer5.7. Ion Cyclotron Resonance 6. Global Mass Spectrometry Analysis, By Industry 6.1. Pharmaceutical6.2. Biotechnology6.3. Space Research6.4. Food Testing 7. Global Mass Spectrometry Analysis, By Geography 7.1. Introduction7.2. North America7.2.1. USA7.2.2. Canada7.2.3. Mexico7.3. South America7.3.1. Brazil7.3.2. Argentina7.3.3. Others7.4. Europe7.4.1. Germany7.4.2. France7.4.3. UK7.4.4. Others7.5. Middle East and Africa7.5.1. Saudi Arabia7.5.2. UAE7.5.3. Others7.6. Asia Pacific7.6.1. China7.6.2. India7.6.3. Japan7.6.4. South Korea7.6.5. Taiwan7.6.6. Thailand7.6.7. Indonesia7.6.8. Others 8. Competitive Environment and Analysis 8.1. Major Players and Strategy Analysis8.2. Emerging Players and Market Lucrativeness8.3. Mergers, Acquisitions, Agreements, and Collaborations8.4. Vendor Competitiveness Matrix 9. Company Profiles 9.1. 908 Devices9.2. AB SCIEX9.3. Advion9.4. Agena Biosciences9.5. Bioflyte9.6. Biognosys9.7. Chiesi9.8. GlaxoSmithKline9.9. Intervenn Biosciences9.10. Sphere Fluidics
For more information about this report visit
Media Contact: Research and MarketsLaura Wood, Senior Manager[email protected] For E.S.T Office Hours Call +1-917-300-0470For U.S./CAN Toll Free Call +1-800-526-8630For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907Fax (outside U.S.): +353-1-481-1716
Logo:
SOURCE Research and Markets
MENAFN23062022003732001241ID1104422737
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.